GeoVax Labs, Inc. (GOVX)

Market Cap	24.63M
Revenue (ttm)	3.09M
Net Income (ttm)	-24.32M
Shares Out	9.44M
EPS (ttm)	-7.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,238,346
Open	2.840
Previous Close	2.910
Day's Range	2.530 - 2.870
52-Week Range	1.090 - 11.180
Beta	3.11
Analysts	Strong Buy
Price Target	14.20 (+444.06%)
Earnings Date	Nov 12, 2024

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM0...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX
• Website: https://www.geovax.com

Analyst Forecast

According to 5 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price forecast is $14.2, which is an increase of 444.06% from the latest price.

Price Target

$14.2

(444.06% upside)

Analyst Consensus: Strong Buy